Related by context. All words. (Click for frequent words.) 64 previously untreated follicular 64 cell acute lymphoblastic 64 acute leukemias 64 CLL SLL 63 Waldenstrom macroglobulinemia 63 relapsed acute lymphoblastic 63 metastatic pancreatic 63 follicular Non Hodgkin 63 HBeAg negative 63 relapsed MM 63 relapsed mantle 62 refractory Hodgkin 62 acute myeloid 62 leukemia ALL 62 refractory indolent non 62 indolent follicular non 61 relapsed Acute Myeloid 61 leukemia AML 61 precursor acute lymphoblastic 61 smoldering myeloma 61 systemic anaplastic large 61 papillary renal cell carcinoma 61 gastrointestinal stromal 61 acute myelogenous 61 Ph + acute lymphoblastic 61 refractory chronic lymphocytic 61 pediatric acute lymphoblastic 61 hereditary pancreatitis 60 lymphoma Hodgkin lymphoma 60 refractory acute myeloid 60 Acute myeloid leukemia 60 ErbB2 positive 60 relapsed leukemia 60 squamous histology 60 malignant brain 60 tumors GIST 60 antiretroviral naïve 60 Jack Linkletter 60 deCODE ProstateCancer TM 60 heavily pretreated 60 HER2 positive metastatic breast 60 HIV coinfected 60 resistant hormone refractory 60 galiximab 60 Acute Myeloid Leukaemia AML 60 Glioblastoma Multiforme 60 Hodgkin lymphoma HL 60 EGFR mutation positive 59 stage IIIb IV 59 hematological cancers notably 59 refractory metastatic 59 untreated metastatic pancreatic 59 recurrent metastatic 59 small lymphocytic lymphoma 59 Medullary thyroid cancer 59 relapsed refractory multiple myeloma 59 recurrent glioblastoma multiforme 59 refractory acute lymphoblastic 59 Anaplastic large 59 de novo AML 59 AML acute myeloid 59 rituximab refractory 59 non hodgkin lymphoma 59 metastatic renal 59 Cell Non Hodgkin 59 myelofibrosis MF 59 metastatic renal cell 59 heavily pretreated patients 59 chronic lymphocytic 59 relapsed refractory 59 Non Hodgkin 59 Chronic lymphocytic leukemia 59 hormone receptor negative 58 advanced hepatocellular carcinoma 58 histologic subtype 58 non Hodgkins Lymphoma 58 lenalidomide Revlimid R 58 refractory acute promyelocytic 58 leukemia lymphoma multiple myeloma 58 advanced metastatic prostate 58 KRAS wild 58 systemic ALCL 58 bladder ovarian 58 relapsed acute myelogenous 58 Follicular lymphoma 58 myelogenous leukemia 58 rituximab refractory follicular 58 Acute lymphocytic leukemia 58 smoldering multiple myeloma 58 metastatic bladder 58 ovarian endometrial 58 T1c 58 KRAS mutations occur 58 childhood acute lymphoblastic 58 Acute myelogenous leukemia 58 follicular lymphoma FL 58 recurrent NSCLC 58 leukemia multiple myeloma 58 non metastatic osteosarcoma 58 visceral metastases 58 diffuse gastric 58 untreated metastatic colorectal 58 underwent surgical resection 58 Chronic lymphocytic leukemia CLL 58 histological subtype 58 Cutaneous T 58 relapsed multiple myeloma 58 Leukemias 58 refractory AML 58 Bezielle 58 forodesine 57 acute lymphoid leukemia 57 metastatic hormone refractory 57 chronic myeloid 57 Leukemia lymphoma 57 infliximab monotherapy 57 lymphoma multiple myeloma 57 oral ridaforolimus 57 metastatic GIST 57 CRp 57 Acute Myelogenous Leukemia AML 57 colorectal lung 57 relapsing remitting MS RRMS 57 BRCA deficient 57 oral clodronate 57 CR nPR 57 lymphoproliferative disorders 57 Adjuvant chemotherapy 57 Philadelphia Chromosome Positive 57 refractory DLBCL 57 juvenile myelomonocytic leukemia 57 hepatorenal syndrome 57 differentiated thyroid 57 leukemia APL 57 advanced carcinoid 57 non Hodgkin lymphomas 57 hormone refractory metastatic prostate 57 MabThera Rituxan 57 Amgen Neulasta R 57 thetreatment 57 achieved ACR# 57 refractory CLL 57 polycythemia vera essential thrombocythemia 57 measurable tumor regressions 57 hepatocellular carcinoma liver 57 NMIBC 57 relapsed refractory AML 57 Flu Cy 57 leukemia myeloma 57 indolent lymphoma 57 intravenous belinostat 57 Chronic myeloid leukemia CML 57 ara C 57 lymphocytic leukemia 57 leukemia lymphomas 57 brivanib 57 relapsed ALL 57 treatment naive genotype 57 cutaneous T 57 stage IIIB IV 57 lymphocytosis 56 cisplatin chemotherapy 56 AML MDS 56 ovarian breast 56 cytarabine daunorubicin 56 Squamous 56 recurrent malignant glioma 56 Glioblastoma multiforme GBM 56 refractory cutaneous T 56 IV malignant melanoma 56 pancreatic adenocarcinoma 56 haematologic malignancies 56 multiple myeloma MM 56 EndoTAGTM 1 56 5-fluorouracil/leucovorin 56 refractory chronic myeloid 56 ELACYT 56 Idiopathic pulmonary fibrosis 56 CCR5 receptor antagonist 56 malignant fibrous histiocytoma 56 coinfected 56 metastatic liver 56 ixabepilone 56 Nonalcoholic fatty liver 56 mitoxantrone plus 56 ZACTIMA 56 metastatic gastric 56 Folfox 56 Alessandro Riva 56 refractory systemic anaplastic 56 pancreatic colon 56 Acute Lymphocytic Leukemia 56 squamous cell carcinoma SCC 56 Diffuse Large B 56 non CF bronchiectasis 56 mRCC 56 gemcitabine carboplatin 56 myeloproliferative neoplasms 56 allogeneic bone marrow 56 advanced metastatic renal 56 refractory lymphoma 56 overt hepatic encephalopathy HE 56 Acute lymphoblastic leukemia 56 lymphoblastic leukemia 56 Lung transplantation 56 dacarbazine DTIC 56 Chronic myeloid leukemia 56 histologies 56 Non Hodgkins lymphoma 56 anthracycline taxane 56 LymphoStat B belimumab 56 % CI #.#-#.# [003] 56 PANVAC VF 56 malignant neoplasm 56 achieved CCyR 56 lymphoma CTCL 56 autoantibody positive 56 leukemia CLL 56 huN# DM1 56 leukemias lymphomas 56 haematologic 56 cervical carcinoma 56 Ribavirin causes 56 HBeAg positive 56 HBeAg negative patients 56 anaplastic astrocytoma 56 drug Treanda 56 relapsed SCLC 56 idiopathic thrombocytopenic purpura 56 resectable pancreatic cancer 56 minimally symptomatic 56 Revlimid pill 56 locoregional recurrence 56 CTAP# Capsules 56 Non Hodgkin lymphoma 56 mcg albinterferon alfa 2b 56 cancer mCRC 56 dasatinib Sprycel ® 56 MELAS 56 myeloproliferative neoplasms MPNs 56 metastatic lung cancer 56 hematologic malignancy 55 BRAF V# mutation 55 severe oral mucositis 55 underwent liver transplantation 55 Omacetaxine 55 leukaemias 55 Relapsed Refractory 55 esthesioneuroblastoma rare form 55 cell chronic lymphocytic 55 LHRH receptor positive 55 Leukemia AML 55 dasatinib Sprycel 55 unresectable Stage III 55 refractory colorectal cancer 55 pilocytic astrocytoma 55 Brentuximab Vedotin SGN 55 rhabdoid 55 liver histology 55 Renal Cell Carcinoma RCC 55 hepatocellular carcinomas 55 null responder HCV 55 mCRPC 55 lintuzumab SGN 55 metastatic malignant 55 alvespimycin 55 neutropenia dehydration dyspnea 55 refractory myeloma 55 diagnosed multiple myeloma 55 CR CRu 55 Aflibercept 55 Fludarabine 55 Multiple Myeloma MM 55 % CI #.#-#.# [007] 55 adjuvant cisplatin 55 lung pancreatic 55 non splenectomized 55 Hurthle cell 55 Wilm tumor 55 demonstrated antitumor activity 55 stage IIIb 55 diagnosed Ph + 55 refractory NSCLC 55 Wegener granulomatosis 55 low dose cytarabine 55 hepatoblastoma 55 Malignant gliomas 55 Tesmilifene 55 metastatic castration resistant 55 SJIA 55 decompensated liver disease 55 rALLy 55 histologically confirmed 55 Annamycin 55 XL# administered orally 55 follicular NHL 55 Phase #/#a trial 55 lymphoma leukemia 55 Follicular Lymphoma 55 metastatic colorectal 55 elacytarabine 55 methotrexate monotherapy 55 relapsed refractory aggressive 55 neoadjuvant treatment 55 castrate resistant 55 thymoma 55 confidence interval #.#-#.# 55 Myelodysplasia 55 PROSTVAC ® 55 untreated multiple myeloma 55 biochemical relapse 55 metastatic kidney 55 renal cell carcinomas 55 HER2 positive metastatic 55 metastatic malignant melanoma 55 reduce serum phosphate 55 Chronic Myelogenous Leukemia CML 55 cell carcinoma RCC 55 commercialize deforolimus 55 EGFR expressing mCRC 55 gastrointestinal stromal tumor GIST 55 SNT-MC#/idebenone 55 Bayer Nexavar 55 thalassemia sickle cell 55 cirrhosis liver failure 55 CTCL 55 lymphomas leukemias 55 soft tissue sarcomas 55 ANCA associated 55 IPAH 55 cyclophosphamide FC 55 IIb IV 55 Wilms tumors 55 8mg/kg 55 sorafenib Nexavar ® 55 operable breast cancer 55 CHOP chemotherapy 55 untreated AML 55 anthracycline containing 55 hematological diseases 55 remission induction 55 K ras mutations 55 glufosfamide 54 nonmetastatic 54 FLT3 mutations 54 MAGE A3 ASCI 54 relapsed CLL 54 Swedish Mammography Cohort 54 HBV infections 54 remission CR 54 acute lymphoblastic 54 BARACLUDE ® 54 leukemia lymphoma sickle cell 54 orally administered inhibitor 54 muscular dystrophy cystic fibrosis 54 grade cervical intraepithelial 54 completely resected 54 biopsy Gleason 54 tumor histology 54 Chronic Lymphocytic Leukemia CLL 54 farletuzumab 54 FluCAM arm 54 post transplant lymphoproliferative 54 % CI #.#-#.# [005] 54 TTR amyloidosis 54 cytoreduction 54 refractory Ph + 54 surgically resectable 54 chemotherapy fludarabine 54 Pneumococcal pneumonia 54 anaplastic astrocytoma AA 54 HER2 expression 54 diagnosed GBM 54 psoriatic arthritis PsA 54 distant metastasis 54 lung colorectal 54 Relapsing remitting MS 54 PNP inhibitor 54 baseline LDH 54 Vicinium TM 54 preoperative chemotherapy 54 paclitaxel cisplatin 54 nonalcoholic steatohepatitis 54 erlotinib Tarceva ® 54 immune thrombocytopenic purpura 54 cell lymphoma CTCL 54 peripheral sensory neuropathy 54 Sudhir Agrawal D.Phil 54 Naive Patients 54 peritoneal cancer 54 decompensated cirrhosis 54 unresectable recurrent 54 imatinib Gleevec ® 54 taxane refractory 54 Myelodysplastic syndromes 54 diabetes mellitus DM 54 bendamustine 54 alpha1 antitrypsin AAT deficiency 54 bortezomib refractory 54 deletion 5q 54 ovarian pancreatic 54 recurrent Hodgkin 54 patients evaluable 54 chronic HBV 54 pCR 54 Acute Lymphoblastic Leukaemia 54 MALT lymphoma 54 FOLFIRI alone 54 Mantle Cell Lymphoma 54 Phase #b/#a clinical 54 PCNSL 54 Rituxan rituximab 54 untreated chronic lymphocytic 54 recurrent bladder 54 unresectable tumors 54 FUSILEV enhances 54 atypical hemolytic uremic syndrome 54 Lymphocytic 54 relapsed follicular 54 HER2 overexpression 54 CHD CVD 54 B CLL 54 Cloretazine 54 Anaplastic 54 Myelodysplastic Syndrome MDS 54 non metastatic resectable 54 Myelodysplastic Syndrome 54 lumiliximab 54 CIMZIA TM 54 nonsmall cell lung cancer 54 melphalan prednisone 54 fallopian tube carcinoma 54 immune thrombocytopenic purpura ITP 54 refractory multiple myeloma 54 gemcitabine Gemzar ® 54 Hepsera adefovir dipivoxil 54 biochemical recurrence 54 pediatric malignancies 54 pertuzumab 54 prior chemotherapy regimens 54 metastatic brain tumor 54 diffuse intrinsic pontine glioma 54 recurrent glioblastoma 54 Phase III randomized controlled 54 epithelial tumors 54 Hodgkin lymphoma NHL 54 HER2 positive cancers 54 Doxil ® 54 eosinophilic asthma 54 relapsed AML 54 TTF Therapy 54 cervical intraepithelial neoplasia 54 SPRYCEL ® 54 Ewings sarcoma 54 prostate carcinoma 53 sunitinib malate 53 haematological cancers 53 Belldegrun 53 Renal cell carcinoma 53 Aplidin 53 PROSTVAC VF 53 Hepatocellular Carcinoma HCC 53 AVASTIN 53 adjuvant radiotherapy 53 Evoltra ® 53 thalidomide Thalomid 53 ovarian germ 53 CYT# potent vascular disrupting 53 carboplatin paclitaxel 53 Response Evaluation Criteria 53 bile duct cancers 53 Cimzia TM 53 chemosensitizer 53 astrocytomas 53 mCRC patients 53 Eliezer Zomer Ph.D. 53 INSPIRE Trial Phase III 53 bortezomib Velcade R 53 myelodysplastic syndrome MDS 53 nonhereditary 53 hypereosinophilic syndrome 53 ACR# responses 53 refractory follicular 53 elotuzumab 53 carcinoid tumors 53 aged ≥ 53 nondiabetic patients 53 HNSCC 53 capecitabine Xeloda 53 precancerous condition 53 abiraterone acetate 53 clinically localized prostate 53 oral FTY# 53 sorafenib Nexavar 53 Oncotype 53 myelodysplastic myeloproliferative diseases 53 AML Leukemia 53 intra arterial chemotherapy 53 advanced HER2 positive 53 PNH patients 53 stage IIIB 53 afatinib 53 diagnosed glioblastoma 53 assessing T DM1 53 antibody MAb 53 gastrointestinal cancers 53 acute myelogenous leukemia AML 53 common hematologic malignancy 53 IR Cysteamine 53 oral squamous cell 53 indicate Schnuphase 53 novel VDA molecule 53 localized renal 53 Chronic pancreatitis 53 essential thrombocythemia 53 comparator arm 53 stage IIIA 53 Kaplan Meier analysis 53 T Cell Lymphoma 53 platinum refractory 53 pancreatic neuroendocrine 53 mesothelioma asbestosis 53 COPEGUS ribavirin 53 mildly symptomatic 53 RECIST criteria 53 unresectable locally advanced 53 HBeAg positive patients 53 adult chronic ITP 53 mycosis fungoides 53 ependymoma 53 de novo kidney transplant 53 Klonoski suffered 53 Soft Tissue Sarcoma 53 receiving chemoradiation therapy 53 hematological malignancy 53 KRAS status 53 Acute Myeloid Leukaemia 53 undergone radical prostatectomy 53 biliary tract cancer 53 cutaneous T cell 53 irinotecan chemotherapy 53 homozygous familial hypercholesterolemia 53 naïve HCV 53 unresectable stage 53 retrospective cohort 53 polyp recurrence 53 MGUS 53 indolent NHL 53 acute GvHD 53 tuberous sclerosis TS 53 neuroendocrine cancers 53 CTEPH 53 lymphoid malignancies 53 premalignant lesion 53 taxane chemotherapy administered 53 ® lenalidomide 53 phase Ib 53 haematological 53 atypical hyperplasia 53 Hurler syndrome 53 locoregional 53 untreated de novo 53 XL# SAR# 53 lintuzumab 53 B Cell Lymphoma 53 dacetuzumab 53 metastatic carcinoid 53 prospectively defined 53 FOLFOX6 53 morphometric vertebral fractures 53 lenalidomide Revlimid 53 chronic idiopathic 53 plus prednisone prednisolone 53 radiation chemoradiation 53 sorafenib tablets 53 CRu 53 late onset Pompe 53 Stage IIB 53 metastatic CRC 53 alemtuzumab treated 53 CALGB 53 carcinoid 53 dosing cohort 53 HBeAg negative chronic hepatitis 53 clinico pathological 53 ribavirin therapy 53 chronic thromboembolic pulmonary 53 vaccine GMK 53 plus gemcitabine 53 nonmelanoma 53 nucleoside naive 53 NPM1 mutations 53 myelofibrosis 53 phase IIb study 53 Genasense ® 53 baminercept 53 pulmonary metastasis 53 breast pancreatic 53 5-FU/LV 53 advanced medullary thyroid 53 Telintra 53 HRPC 53 adverse cytogenetics 53 nonalcoholic steatohepatitis NASH 53 advanced adenoma 53 Enzastaurin 53 kidney urologic 53 estramustine 53 faulty BRCA2 gene 53 metastatic CRPC 53 hormone refractory prostate 53 oral ghrelin agonist 53 oligodendrogliomas 53 MGd 53 ER CHOP 53 Insegia 53 cause mesothelioma asbestosis 53 EGFR expressing 53 HIV uninfected 53 EFAPROXYN 53 rALLy clinical trial 53 Acute myeloid leukemia AML 53 BCIRG 53 LHRH agonists 53 protease inhibitor PI 53 polyarticular 53 Campath alemtuzumab 53 panobinostat 53 axitinib 53 imatinib therapy 53 chlorambucil 53 graft dysfunction 53 Pneumococcal vaccines 53 CDH1 53 metastatic renal cell carcinoma 53 carcinoma mCRC 53 Acute Myelogenous Leukemia 53 Fanconi syndrome 52 severe exacerbations 52 Refractory Hodgkin Lymphoma 52 multiple myeloma 52 myeloid leukemia 52 Relapsing Remitting MS 52 tainted blood transfusion 52 PAOD 52 temozolomide TMZ 52 follicular non 52 Allovectin 7 ® 52 Cell Lymphoma 52 underwent resection 52 syngeneic 52 diagnosed 52 adenomatous polyps 52 alveolar soft 52 gefitinib Iressa 52 systemic autoimmune 52 Velcade bortezomib 52 Ishak fibrosis score 52 hyperphenylalaninemia HPA due 52 OHR/AVR# 52 placebo controlled clinical 52 evaluating mipomersen 52 treatment naïve genotype 52 splenectomized patients 52 grade glioma 52 sargramostim 52 chronic HCV genotype 52 HER2 positive 52 metastic 52 Peginterferon alfa 2b 52 idiopathic PAH 52 grade cervical dysplasia 52 pleural mesothelioma 52 Sezary syndrome 52 neratinib 52 haemolytic uraemic syndrome 52 adjuvant systemic 52 MCyR 52 metastatic dermatofibrosarcoma protuberans DFSP 52 Newly Diagnosed Multiple Myeloma 52 cell lymphoma ALCL 52 Zolinza 52 HNPCC 52 neurologic progression 52 undetectable HBV DNA 52 primary humoral immunodeficiency 52 trastuzumab Herceptin ® 52 liposomal amphotericin B 52 hA# 52 pancreatic islet cell 52 refractory SCLC 52 Relapsed Refractory Aggressive 52 Venous thromboembolism 52 receiving golimumab 52 pomalidomide 52 basal cell nevus syndrome 52 pancreatic insufficiency 52 BRAF V#E mutation 52 Ewing sarcoma bone 52 neutropenic sepsis 52 intraepithelial neoplasia 52 pheochromocytomas 52 metastatic bone 52 temsirolimus 52 hereditary deficiency 52 osteosarcomas 52 MDS AML 52 lupus erythematosus 52 Vandetanib 52 zanolimumab 52 Onrigin 52 chronic idiopathic thrombocytopenic purpura 52 Severe Primary IGFD 52 % Confidence Interval 52 treating chronic myeloid 52 cell malignancies 52 basal cell carcinoma BCC 52 trial evaluating Prochymal 52 inherited neurodegenerative 52 progression TTP 52 gastrointestinal stromal tumors 52 peritoneal carcinomatosis 52 Pharmacokinetics PK 52 alfa 2a 52 BCG refractory 52 genotypic resistance 52 ThermoDox R 52 enzastaurin 52 myeloproliferative diseases 52 glioblastoma multiforme GBM 52 pegylated liposomal doxorubicin 52 progressive neurodegenerative 52 FOLFOX6 chemotherapy regimen 52 docetaxel chemotherapy 52 pegylated interferon alpha 52 Glioblastoma Multiforme GBM 52 HER2 + 52 breast carcinomas 52 dirucotide MBP# 52 medulla blastoma 52 unique alkylating agent 52 JMML 52 rheumatoid arthritis osteoarthritis ankylosing 52 adalimumab Humira 52 acute lymphatic leukemia 52 relapsing multiple sclerosis 52 BRCA1 mutation carriers 52 doublet chemotherapy 52 thrombocytopenic 52 oropharyngeal candidiasis OPC 52 histological subtypes 52 Metastatic breast cancer 52 BRIM2 52 HCV infections 52 Phase Ib clinical 52 Median progression 52 C1 INH deficiency 52 refractory Hodgkin lymphoma 52 HCV infection 52 GRN# 52 histologically proven 52 endoscopic remission 52 refractory peripheral T 52 PROCRIT ® 52 non resectable metastatic 52 Acute Leukemia 52 antiepileptic medications 52 oral TLR7 agonist prodrug 52 lymphoma 52 Xanafide 52 CD# mAb 52 AKT inhibitor 52 radezolid 52 ipsilateral breast 52 acute STEMI 52 refractory rituximab naive 52 Alagille syndrome 52 oblimersen 52 HER2 negative 52 nonsquamous 52 lobular cancer 52 Scale EDSS 52 autologous transplants 52 grade serous ovarian 52 chronic HBV infection 52 hematologic 52 elevated ALT 52 Pancreatic neuroendocrine tumors 52 Castration Resistant Prostate Cancer 52 Amrubicin 52 Phase Ib IIa 52 LV dysfunction 52 malignant lymphoma 52 EGFR expressing metastatic colorectal 52 PPAR gamma agonist 52 Glioma 52 anthracyclines taxanes 52 sirtuin inhibitor program 52 leukemia aplastic anemia 52 pamidronate 52 chronic HCV 52 histone deacetylase HDAC inhibitor 52 plus methotrexate 52 virus HCV infection 52 LUX Lung 52 radiotherapy RT 52 HCV infected 52 receptor tyrosine kinase inhibitor 52 Neuvenge 52 Uncontrolled hypertension 52 hematologic disorders 52 Virulizin ® 52 Adjuvant therapy 52 pheochromocytoma 52 Cloretazine R VNP#M 52 advanced neoplasia 52 PITX2 methylation 52 lymphoblastic lymphoma 52 liver metastasis 52 dose escalation phase 52 hematologic toxicity 52 INCB# [001] 52 vidofludimus 52 CIMZIA TM certolizumab pegol 52 neuroendocrine carcinoma 52 evaluating tivozanib 52 nasal pharyngeal cancer 52 neoadjuvant therapy 52 PSMA ADC 52 prognostic indicators 52 glycated hemoglobin levels 52 lymphopenia 52 curative resection 52 PegIFN RBV 52 cytogenetic response 52 methotrexate therapy 52 response pCR 52 coinfected patients 52 #mg ATC 52 DOXIL 52 pancreatic enzyme supplements 52 relapsed Hodgkin lymphoma 52 BMPR2 52 underwent CABG 51 unfavorable cytogenetics 51 mucinous 51 metastatic castrate resistant 51 gastrin analogue TT 51 nonmelanoma skin cancers 51 CVP cyclophosphamide vincristine 51 genitourinary GU 51 Bcr Abl T#I mutation 51 onset diabetes mellitus 51 lung cancer NSCLC 51 preoperative PSA 51 vandetanib 51 bladder carcinoma 51 refractory indolent NHL 51 immunomodulatory therapy 51 chronic granulomatous disease 51 PDGFRA 51 sustained virological response 51 mCRC acneform rash 51 refractory APL 51 Jevtana 51 gemcitabine cisplatin 51 complete remissions 51 certolizumab 51 cisplatin resistant 51 Major Depressive Disorder MDD 51 blastic 51 BEXXAR Therapeutic Regimen 51 DIPG 51 hematopoietic cancers 51 primary hypercholesterolemia 51 Vidaza ® 51 idiopathic pulmonary arterial hypertension 51 Cloretazine ® 51 IIa trial 51 Panzem R NCD 51 Canvaxin TM 51 chronic lymphocytic leukemia CLL 51 cisplatin gemcitabine 51 transplantation HCT 51 partial remissions 51 autosomal recessive genetic 51 Surgical resection 51 recovery CRp 51 abnormal cytology 51 paclitaxel Taxol R 51 chronic ITP patients 51 Personalized Immunotherapy 51 pharyngeal cancer 51 ZOLINZA 51 complete cytogenetic response 51 Acute Promyelocytic Leukemia 51 evaluable patients 51 chronically immunosuppressed solid 51 HGS# 51 pT2 51 RTOG 51 antiangiogenic therapy 51 perifosine 51 Idiopathic Pulmonary Fibrosis 51 advanced epithelial ovarian 51 gemcitabine chemotherapy 51 plus prednisone 51 hematological disorders 51 cyclophosphamide doxorubicin vincristine 51 clinicopathological features 51 lobular carcinoma 51 Arch Intern Med 51 Cojocaru correspondent 51 acute mania 51 myasthenia gravis neuromuscular 51 fluoropyrimidine 51 HIV HCV coinfected 51 Temodar ® 51 cART 51 DEB# 51 EDEMA3 51 adjunctive placebo 51 chemoradiotherapy 51 hormone receptor status 51 endometrioid 51 herpes zoster shingles 51 aldosterone antagonist 51 placebo dexamethasone 51 radiolabeled TM# 51 taxane chemotherapy 51 combination antiretroviral therapy 51 underwent radical prostatectomy 51 CIMZIA ™ 51 NOMID 51 Camptosar ® 51 debulking surgery 51 refractory CTCL 51 pancytopenia 51 polycythemia vera PV 51 Troxatyl 51 invasive ductal 51 androgen receptor antagonist 51 oral deforolimus 51 NYHA Class II 51 aflibercept 51 Azacitidine 51 prior nephrectomy 51 RhuDex R 51 Cytoxan 51 endometrial adenocarcinoma 51 multivariable adjusted 51 opsoclonus myoclonus syndrome 51 moderate renal impairment 51 Adenocarcinoma 51 xenograft models 51 Xelox 51 Elacytarabine 51 refractory anaplastic astrocytoma 51 BRAF gene mutations 51 achieved sustained virological 51 relapsing remitting 51 Arzerra ofatumumab 51 intravenous bisphosphonates 51 cytogenetic responses 51 allogeneic transplant 51 hepatitis C genotype 51 pretransplant 51 non squamous 51 Pulmonary arterial hypertension 51 Gemzar ® 51 Aplastic anemia 51 cyclophosphamide methotrexate 51 portal vein thrombosis 51 Pegylated Interferon 51 standard chemotherapy regimen 51 Cholangiocarcinoma 51 pancreatic colorectal 51 treating sarcoma testicular 51 Dacogen injection 51 phase IIb trial 51 Astrocytoma 51 RhuDex ™ 51 chronic hepatitis cirrhosis 51 unresectable 51 pT3 51 cranial radiation 51 diagnosed chronic myeloid 51 pain palliation 51 cholangiocarcinoma 51 recurrent GBM 51 diabetic kidney 51 iniparib 51 DLBCL 51 Cytarabine Liposome Injection 51 febrile neutropenia 51 chronic eosinophilic leukemia 51 Nicole Onetto MD 51 Herceptin trastuzumab 51 mutated BRAF gene